News

Latest news

Hide mandatory notifications of trade

GLOBVAC Awards NOK 7.7 Million to Bionor Pharma for Research on Vacc-HIV

Bergen 17.08.2013 - Bionor Pharma ASA (OSE: BIONOR) announces that the earlier announced grant from GLOBVAC for partial funding of the Vacc-HIV project (please see release published 21 June) has been confirmed and will be funded with NOK 7.7 mill. Support from GLOBVAC help to advance HIV therapeutic vaccine research towards a functional cure

Vacc-HIV combines Bionor Pharma’s two therapeutic HIV vaccine candidates Vacc-4x and Vacc-C5. Vacc-HIV aims to induce immune cells that can kill virus infected cells (Vacc-4x) and generate antibodies to reduce hyper immune activation caused by HIV (Vacc-C5). The Vacc-HIV studies funded by the grant from GLOBVAC will be carried out in collaboration with St. George’s University, London, St Georges Healthcare NHS Trust and the University of Lausanne in Switzerland.

Bionor Pharma will give an overall presentation of the status and expectations of the ongoing and planned HIV research program at the GLOBVAC conference today. Two of Bionor Pharma’s projects are supported by GLOBVAC. The Company’s main objective is to reach a functional cure for HIV which will enable people to live long-term with no disease progression nor viral transmission in the absence of ongoing combination antiretroviral therapy, cART.

“We are grateful for the support from GLOBVAC which has encouraged the organization and been of substantial value to our HIV research program” said Maja Sommerfelt, Chief Scientific Officer, Bionor Pharma. “This support has contributed to the Company’s leading position in development of therapeutic HIV vaccines”. 
The presentation held at today’s conference will be available at Bionor Pharma’s webpage.

Bionor Pharma ASA

Synne H Røine
CFO

Tel +47 99 22 98 92


About Bionor Pharma ASA
Bionor Pharma is a leading biotechnology company, searching for breakthrough products for the treatment and prevention of life-threatening viral diseases. The Company is listed on the Oslo Stock Exchange, and is developing vaccines for viral infections. The vaccines are based on a proprietary technology platform developed following more than two decades of research into peptides, and they are designed to safely stimulate the immune system to combat viral diseases.

Global leader in the development of HIV vaccines
The Company has a leading position in the global research field for therapeutic HIV vaccines, and has two vaccine candidates in the clinical stage of development: Vacc-4x aims to induce long lasting virus control by training immune cells to seek out and kill virus-producing cells, and Vacc-C5 is designed to induce antibodies to HIV that can reduce the harmful hyperactivation of the immune system which can lead to AIDS. The foremost candidate, Vacc-4x, has shown a statistically significant reduction in viral load in a phase II randomized, multinational, double-blind, placebo-controlled study. The Company’s innovative technology platform is also well positioned to develop vaccines for other viral diseases, such as Influenza, HCV (Hepatitis C), HPV (Human papillomavirus) and CMV (Cytomegalovirus).

Vaccine candidates in development
HIV vaccine, Vacc-4x: 1. Clinical Phase II study, combining Vacc-4x with Celgene’s immune modulator lenalidomide (Revlimid®), to investigate whether lenalidomide enhances the effect of Vacc-4x in this placebo-controlled study in HIV patients with an impaired immune system.
2. Clinical Phase II study, with Reboost in patients from the previous phase II study, aimed at reducing viral load even further.
3. Planned clinical Phase I/II study, combining Vacc-4x with Celgene’s HDAC inhibitor (HDACi) Romidepsin, to reactivate and remove latent HIV infected cells from the reservoirs.

HIV vaccine, Vacc-C5: Clinical Phase I/II study, to investigate safety and whether the vaccine induces antibodies against HIV in humans.

HIV vaccine, Vacc-HIV (combination of Vacc-4x and Vacc-C5): A preclinical study is in preparation. The rationale behind Vacc-HIV is that this combination should prove more efficacious than each vaccine individually.

Universal influenza vaccine, Vacc-Flu: This vaccine is in the preclinical phase of development. Vacc-Flu is designed to produce long lasting immunity, and to be effective against all seasonal variations of influenza A.

More information about Bionor Pharma is available at www.bionorpharma.com

This information is subject to the disclosure requirements of §5-12 vphl
(Norwegian Securities Trading Act).  Vacc-4x, Vacc-C5, Vacc-HIV, Vacc-Flu, Vacc-HCV, Vacc-CMV and Vacc-HPV are currently investigational treatments that have not been approved for marketing by any regulatory authority.